Pharmaceuticals

Global Non Hodgkin Lymphoma (NHL) Market Forecast 2026–2035 Presenting Long-Term Growth Insights

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Non Hodgkin Lymphoma (NHL) Market At The End Of The 2026–2030 Forecast Period?

The non-Hodgkin lymphoma (NHL) market has experienced substantial growth in recent years. Its value is projected to increase from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The expansion observed in prior periods is attributable to several factors, including a global rise in NHL cases, advancements in chemotherapy treatments, increased healthcare spending, greater public understanding of lymphatic cancers, and the development of oncology hospital facilities.

The non-Hodgkin lymphoma (NHL) market size is anticipated to undergo significant expansion in the coming years, projected to reach $16.44 billion by 2030, with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is attributable to the expanding pipeline of targeted therapies, a rise in biologic approvals, increasing adoption of personalized medicine, broadening access in emerging markets, and an uptick in stem cell transplant procedures. Key trends expected in this period include the rising uptake of immunotherapy and targeted therapy, more widespread use of combination treatment regimens, an increased focus on early and accurate diagnosis, the expansion of personalized treatment protocols, and a shift towards outpatient and home-based care models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Drivers Are Shaping The Future Growth Of The Non Hodgkin Lymphoma (NHL) Market?

The non-Hodgkin lymphoma market is expected to grow, primarily driven by the high prevalence of non-Hodgkin lymphoma. This cancer originates in the lymphatic system, which is an integral part of your immune system. The prevalence of non-Hodgkin lymphoma indicates the number of individuals in a population currently diagnosed with or living with the condition at a specific time. Treatments for non-Hodgkin lymphoma aid in improving outcomes for those already diagnosed by targeting and managing cancer cells. For instance, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma represents 4% of all cancers. Additionally, it is projected to affect around 80,550 Americans in 2023, consisting of 44,880 males and 35,670 females. The organization further estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Therefore, the significant prevalence of non-Hodgkin lymphoma is a key factor driving the non-Hodgkin lymphoma market.

What Segment Types Make Up The Non Hodgkin Lymphoma (NHL) Market?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Which Market Trends Are Creating New Opportunities In The Non Hodgkin Lymphoma (NHL) Market?

Major companies within the non-Hodgkin lymphoma market are increasingly concentrating on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to achieve a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy specifically designed to target CD20-expressing B-cell malignancies, demonstrating promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For example, in November 2023, AbbVie Inc., a US-based pharmaceutical company, secured a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These recent updates are substantiated by previously announced outcomes from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients afflicted with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.

Who Are The Key Players Driving Competition In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Read the full non hodgkin lymphoma (nhl) market report here:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Geographic Regions Are Influencing Demand In The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non Hodgkin Lymphoma (NHL) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795